| Field | Specification |
|---|---|
| Mfr No | |
| Species |
NCH612 is a patient-derived oligodendrocytic cell line that originates from human brain tissue and serves as a relevant research model for anaplastic oligodendroglioma (WHO grade III). This cell line harbors the IDH1 R132H mutation, a hallmark genetic alteration frequently associated with oligodendrogliomas. The mutation leads to epigenetic modifications, including the glioma CpG island methylator phenotype (G-CIMP), which contributes to tumor development and progression. Notably, NCH612 exhibits a partial deletion of chromosome arms 1p and 19q, a genetic characteristic commonly found in oligodendrogliomas and associated with better prognosis and response to certain therapies.
Studies have demonstrated that NCH612 is particularly sensitive to the DNA methyltransferase inhibitor decitabine (DAC). Treatment with DAC results in reduced cell proliferation and colony formation, primarily through the downregulation of TERT (telomerase reverse transcriptase) and the upregulation of p21, a cyclin-dependent kinase inhibitor involved in the DNA damage response. Interestingly, this sensitivity appears to be linked to the presence of both the IDH1 mutation and 1p/19q codeletion, as other IDH1-mutant glioma cell lines without this deletion, such as NCH1681, exhibit resistance to DAC. These findings suggest that epigenetic therapies like DAC could be particularly effective in IDH1-mutant anaplastic oligodendrogliomas with 1p/19q codeletion.
Further molecular investigations reveal that DAC treatment in NCH612 cells leads to the enrichment of pathways related to DNA replication, cell cycle regulation, and lysosomal function, shedding light on the drug’s mechanism of action. The repression of TERT by DAC is mediated by p21, emphasizing the critical role of this pathway in the response to epigenetic therapy. Given its well-defined genetic and epigenetic profile, NCH612 represents a valuable in vitro model for studying the biology of anaplastic oligodendrogliomas and for developing targeted therapies aimed at IDH1-mutant tumors with 1p/19q codeletion.
—
- cultureMedium: DMEM:Ham's F12 (1:1), w: 3.1 g/L Glucose, w: 2.5 mM L-Glutamine, w: 15 mM HEPES, w: 0.5 mM Sodium pyruvate, w: 1.2 g/L NaHCO3 (Cytion article number 820400a)
- supplements: Supplement the medium with 10% FBS, 5 mg/L Heparin, 20 ng/mL bFGF, 20 microgram/L EGF, 5 mg/L Insulin, 100 mg/L Transferrin, 5,2 microgram/L Na-selenit, 6,3 microgram/L Progesteron, 161,1 microgram/L Putrescin, 50 mg/L Hydrocortinson
- subculturing: For subculturing spheroid cultures, begin by mechanically dissociating the spheroids through pipetting up and down 5 to 10 times using an Eppendorf pipette with 1000 μl filter tips. After this, centrifuge the mixture at 300g for 5 minutes at room temperature to pellet the cells. Discard the supernatant and resuspend the cell pellet in fresh culture medium. Finally, transfer the resuspended cells into new culture vessels to promote further spheroid formation. This approach ensures efficient spheroid breakdown and readies them for continued growth in a new environment.
- seedingDensity: 1 x 105 cells/mL
- fluidRenewal: Fresh medium must be added every 2to3 days (2to5 ml depending on the size of the cell culture flask).
- postThawRecovery: Slow. After thawing allow the cells to recover from the freezing process for at least 48 hours.
- freezeMedium: As a cryopreservation medium, use 50% basal medium + 40% FBS + 10% DMSO, or CM-1 (Cytion catalog number 800100), which includes optimized osmoprotectants and metabolic stabilizers to enhance recovery and reduce cryo-induced stress.
10%
OFF
15%OFF
20%
OFF
$50
OFF
FREE
SAMPLE
